Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00975806 · ClinicalTrials.gov registry record · Phase 1
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00975806 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 16 participants.
The verdict
NCT00975806, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with renal cell carcinoma.
Interventions
- DRUG Lenalidomide
- DRUG Sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-09-01 |
| Est. Completion | 2011-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00975806
The ClinicalTrials.gov registry entry for NCT00975806 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT00975806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00975806 about?
NCT00975806 is a clinical study titled "Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma". The purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with renal cell carcinoma.
What is the current status of trial NCT00975806?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-09-01. Estimated completion is 2011-10-01.
What interventions are being tested in trial NCT00975806?
The interventions under investigation include: Lenalidomide (DRUG), Sunitinib (DRUG).
Who is sponsoring clinical trial NCT00975806?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.